Tris Pharma to Showcase Encore Phase 3 Data for Acute Pain Treatment at ASRA 2026

Cebranopadol, a first-in-class dual NOP/MOP receptor agonist, demonstrates significant pain reduction with a favorable safety profile.

Apr. 8, 2026 at 11:52am

Got story updates? Submit your updates here. ›

Tris Pharma, a commercial-stage biopharmaceutical company, announced that it will present data from two Phase 3 trials supporting the efficacy of cebranopadol, an investigational dual-NMR agonist, in treating moderate-to-severe pain following surgical procedures. The company will also host a symposium highlighting the latest clinical evidence on this novel pain management approach at the upcoming ASRA 2026 meeting in Phoenix.

Why it matters

Cebranopadol's unique mechanism of action, which activates both the NOP and MOP receptors, has the potential to provide effective pain relief while reducing the risks of abuse, dependence, and overdose associated with traditional opioid analgesics. This could represent a significant advancement in the treatment of acute pain.

The details

The Phase 3 data to be presented will demonstrate cebranopadol's ability to significantly and sustainably reduce pain following abdominoplasty and bunionectomy procedures. Tris Pharma will also host a symposium exploring the potential of dual-NMR agonists, a promising new class of analgesics, to transform pain management by offering potent analgesia with a lower risk of opioid-related side effects.

  • The ASRA 2026 meeting will take place from April 16 to April 18, 2026, in Phoenix, Arizona.
  • Tris Pharma's poster presentation will be held on Friday, April 17 at 4:30PM - 6:00PM.
  • Tris Pharma's symposium on dual-NMR agonists will be held on April 16, 2026, at 12:15PM - 1:00PM.

The players

Tris Pharma, Inc.

A commercial-stage biopharmaceutical company that is applying its drug development capabilities and proprietary technologies to transform the treatment of ADHD, pain, addiction, and disorders of the central nervous system.

Cebranopadol

An investigational first-of-its-kind dual NOP/MOP receptor (dual-NMR) agonist that uses a novel approach of activating NOP and MOP receptors to work synergistically to treat pain with the potential of a lower risk of abuse, dependence, and overdose.

Jeffrey Gudin, MD

A presenter at the Tris Pharma symposium and a pain therapy researcher from the University of Miami Miller School of Medicine.

Eugene Viscusi, MD

A presenter at the Tris Pharma symposium and a pain therapy researcher from Thomas Jefferson University.

Todd Bertoch, MD

The Chief Medical Officer of CenExel Clinical Research and the Principal Investigator on the ALLEVIATE-2 study for cebranopadol.

Got photos? Submit your photos here. ›

What they’re saying

“We look forward to participating in ASRA's spring meeting and presenting the impressive pivotal data for cebranopadol's potential as a treatment option that prioritizes both efficacy and safety.”

— James Hackworth, Ph.D., Cebranopadol Development Lead

“We are excited to engage with the medical community at ASRA and highlight the potential of dual-NMR agonists to dramatically change how we treat pain.”

— Ketan Mehta, Founder and CEO at Tris Pharma

What’s next

The FDA has granted Fast Track Designation to cebranopadol for chronic low back pain, and if approved, it could become the first dual-NMR pain-relief therapy with the potential to provide efficacy equivalent to selective MOP agonists such as oxycodone with less risk of misuse or physical dependence, addiction or overdose.

The takeaway

Cebranopadol's novel dual-NMR mechanism of action represents a promising new approach to treating acute pain that could offer effective analgesia with a reduced risk of opioid-related side effects. The data presented at ASRA 2026 will be closely watched as the medical community evaluates this potential breakthrough in pain management.